Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Rhea-AI Summary

Agios Pharmaceuticals (Nasdaq: AGIO) will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 1:20 p.m. ET. The company, known for its work in cellular metabolism and PK activation for rare diseases, will have its presentation webcast live on its website. The replay of this webcast will be available for at least two weeks post-event.

Positive

• Agios will present at a high-profile event, boosting its visibility.
• Increased exposure to potential investors and partners from the healthcare sector.
• The presentation will be webcast live and archived, enhancing accessibility and reach.

Negative

• No new financial or clinical data provided in the announcement.
• No immediate direct impact on stock performance from the event itself.

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:

Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Dan Budwick
1AB
dan@1abmedia.com

FAQ

When will Agios present at the Goldman Sachs Global Healthcare Conference?

Agios will present on June 10, 2024, at 1:20 p.m. ET.

How can I access the Agios presentation at the Goldman Sachs Global Healthcare Conference?

A live webcast will be available under 'Events & Presentations' on Agios's website and archived for two weeks.

What is the significance of Agios presenting at the Goldman Sachs Healthcare Conference?

The presentation at a prominent event increases Agios's visibility among potential investors and partners.

What is Agios Pharmaceuticals known for?

Agios specializes in cellular metabolism and PK activation therapies for rare diseases.